Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cel-Sci Corp (CVM)

Cel-Sci Corp (CVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cel-Sci Corp 8229 BOONE BLVD . SUITE 802 VIENNA VA 22182 USA

www.cel-sci.com P: 703-506-9460

Sector:

Medical

Description:

CEL-SCI CORP. was formed to acquire and finance research and development of natural human interleukin-2 (``IL-2``) and lymphokine-related products and processes using the Co.'s proprietary cell culture technologies. The Co.'s proprietary product is sometimes referred to as MULTIKINEn, or buffy-coat interleukins, which is a combination, or ``cocktail`` of IL-2 and certain lymphokines and cytokines. MULTIKINE is a trade name of Co. Since its inception the focus of the Co.'s product development efforts has been on conducting clinical trials to test its proprietary technologies.

Key Statistics

Overview:

Market Capitalization, $K 41,203
Enterprise Value, $K 30,253
Shares Outstanding, K 8,409
Float, K 7,574
% Float 90.07%
Short Interest, K 406
Short Float 4.83%
Days to Cover 6.75
Short Volume Ratio 0.58
% of Insider Shareholders 9.93%
% of Institutional Shareholders 12.08%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -25,410 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,100 K
EBIT, $ -24,800 K
EBITDA, $ -20,910 K

Growth:

1-Year Return -59.68%
3-Year Return -94.63%
5-Year Return -99.18%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth 71.78%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.36 on 08/14/25
Next Earnings Date 02/13/26
Earnings Per Share ttm -7.06
EPS Growth vs. Prev Qtr 43.39%
EPS Growth vs. Prev Year 67.65%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 05/20/25

CVM Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -240.36%
Return-on-Assets % -105.88%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.98
Book Value/Share 2.32
Interest Coverage -38.09
60-Month Beta 0.77
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar